Most SSRI ranges in the PCD market carry immediate-release Paroxetine and stop there — leaving a real gap for the prescriber whose patient discontinued treatment due to early nausea, which is the single most common reason Paroxetine gets switched away from at initiation. RUPATINE CR 25 fills that gap with a controlled-release formulation, and gives a neuropsychiatry-focused distributor a specific product to lead with rather than another generic entrant. Also available as RUPATINE CR 12.5.
Product Specifications
Brand Name: RUPATINE CR 25 (also available as RUPATINE CR 12.5)
Composition: Paroxetine Hydrochloride 25 mg, Controlled Release
Dosage Form: Controlled Release Tablet
Therapeutic Category: Neuropsychiatry, CNS
Manufacturing: WHO-GMP certified facility
Prescription Status: Schedule H
Franchise Availability: Neuropsychiatry PCD Franchise, district-wise monopoly
Composition
Paroxetine Hydrochloride — 25 mg, Controlled Release — SSRI formulated to delay and spread absorption, reducing the early-nausea profile associated with the immediate-release form
The Commercial Case for a Controlled-Release SSRI
Immediate-release Paroxetine reaches peak plasma concentration quickly, and much of its characteristic early nausea is tied directly to that peak. This is the single most common reason patients discontinue in the first weeks — before the antidepressant effect has had time to establish. The controlled-release matrix delays release until the tablet passes into the small intestine, spreading absorption and reducing that peak without changing total daily exposure.
For a franchise partner, this translates into a specific pitch: a prescriber who has already lost a patient to poor SSRI tolerability is actively looking for an alternative, not comparing price between equivalent brands. That is a different, less price-sensitive conversation than the rest of the antidepressant category offers.
Strength Ladder — RUPATINE CR 12.5 and RUPATINE CR 25
Carrying both strengths lets a prescriber initiate on RUPATINE CR 12.5 — the lower dose preferred in the elderly or tolerability-sensitive patients — and titrate to RUPATINE CR 25 for standard maintenance, without the prescription leaving the range at any point in that progression.
Clinical Applications
- Major depressive disorder
- Panic disorder, with or without agoraphobia
- Social anxiety disorder
- Premenstrual dysphoric disorder, as prescribed
- Generalized anxiety disorder, under specialist assessment
Target Prescriber Base
Psychiatrists are the primary call point, particularly for patients who have not tolerated immediate-release SSRIs at initiation — this is the specific opening a field team can use. General Physicians represent secondary coverage for depression and anxiety presentations before specialist referral.
Key Safety Points for Field Detailing
Paroxetine has the shortest half-life among commonly used SSRIs, making abrupt discontinuation more likely to cause withdrawal symptoms — worth flagging to prescribers so tapering is planned in advance. It also carries specific caution in pregnancy and must not be combined with MAOIs. This is a Schedule H drug, dispensed only against a valid prescription.
Why Distributors and MRs in Neuropsychiatry Choose Eridanus Healthcare
RUPATINE CR is positioned within Eridanus Healthcare's core neuropsychiatry PCD franchise range, built specifically for distributors and medical representatives with prior experience calling on psychiatrists and neurologists.
WHO-GMP certified manufacturing across the range, not a selected few products.
Monopoly rights contractually guaranteed on a district-wise basis, not offered subject to later renegotiation.
400+ SKUs spanning neuropsychiatry, CNS, general medicine, gastroenterology, orthopaedics and nutraceuticals — a complete range under one company.
Order processing within 24 hours, reducing the stock delays that undermine prescriber confidence.
A complete promotional kit — visual aids, MR bags, samples, doctor cards, quarterly and festival gifting, and full detailing material for every new launch.
A dedicated relationship manager for ongoing coordination.
Zero franchise fee and zero renewal charge.
Neuropsychiatry PCD Franchise Availability
RUPATINE CR 12.5 and RUPATINE CR 25 are available for PCD Pharma Franchise across India on a district-wise monopoly basis. Distributors and medical representatives with a neuropsychiatry background are specifically encouraged to enquire. Trade enquiries may be directed to Eridanus Healthcare.
Frequently Asked Questions
What is the PCD Pharma Franchise opportunity for Paroxetine CR?
Controlled-release Paroxetine addresses a tolerability gap that most competing neuropsychiatry ranges leave unfilled, giving a franchise partner a genuine differentiator rather than another SSRI competing purely on rate.
Why should a distributor add RUPATINE CR to an existing antidepressant range?
It gives the field team a specific answer for prescribers whose patients have discontinued other SSRIs due to early tolerability issues — a conversation distinct from price negotiation.
Is monopoly available on a district-wise basis?
Yes. Monopoly rights are offered on a district-wise basis and are contractually guaranteed.
Can a medical representative with neuropsychiatry experience apply for a franchise?
Yes. MRs with a background calling on psychiatrists and neurologists are specifically encouraged to apply, as that prescriber relationship translates directly into this business.
Is there a franchise fee or renewal charge?
No. There is no upfront franchise fee and no renewal charge for continuing the association.
What promotional support is provided to franchise partners?
A complete kit including visual aids, MR bags, samples, doctor cards, quarterly and festival gifting, and full detailing material for every new launch, with a dedicated relationship manager for coordination.
Is RUPATINE CR 12.5 also available for franchise?
Yes, alongside RUPATINE CR 25, covering the full initiation and maintenance dosing range under one brand.
How can a distributor apply for neuropsychiatry PCD franchise rights?
Distributors and pharmaceutical professionals holding a valid Drug Licence and GST registration may contact Eridanus Healthcare to discuss territory availability and franchise terms.
Related Products
RUPATINE CR 12.5 (Paroxetine Hydrochloride CR 12.5mg)
This page is intended for pharmaceutical distributors, wholesalers, and healthcare professionals. Product information is provided for commercial and educational reference and is not a substitute for professional medical advice. Eridanus Healthcare does not sell directly to patients. This is a Schedule H drug — to be sold by retail only on the prescription of a Registered Medical Practitioner. All trade enquiries are subject to valid Drug Licence and GST verification.